STE · Full Picture

STERIS plc — the full picture

Earnings window · 2026-07-17 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Segment Revenue Performance · Revenue growth & mixPriority 79
    +18.0% revenue (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Total recurring revenues in Q1 FY2027 were $1,229.6 million (consumables $474.0 million and service $755.5 million) and capital equipment revenue was $263.2 million.
  2. Guidance / Outlook · Guidance & outlookPriority 77
    +6.4% revenue; 2 sources (news, press_release); 3 forward row(s); quote_verified
    Adjusted net income from continuing operations per diluted share for FY 2027 is estimated at $11.10 - $11.30, with net income from continuing operations per diluted share estimated at $8.92 - $9.12 and adjustments for amortization of acquired intangible assets of 2.08 and restructuring charges of 0.07.
  3. Headcount / Restructuring · Restructuring & impairmentPriority 68
    -3.6% operating_income; 2 sources (news, sec_filing); 6 forward row(s); quote_verified
    The August 5, 2026 restructuring is expected to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges; completion anticipated during fiscal 2030.
  4. Capital Expenditure Outlook · UnclassifiedPriority 66
    2 forward row(s); quote_verified
    Capital expenditures are now anticipated to be approximately $450 million compared with prior expectations of $375 million.
  5. Operating Cash Flow Trends · Cash flow generationPriority 66
    2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
    Free cash flow for fiscal 2027 is now expected to be approximately $800 million compared with prior expectations of $850 million.
  6. Products and Technology · Products & launchesPriority 63
    2 sources (press_release, sec_filing); quote_verified
    The August 5, 2026 restructuring investment strengthens Healthcare and Life Sciences formulated chemistries businesses, which together generate more than $700 million in annual revenue.
  7. Restructuring and Facility Consolidation · Restructuring & impairmentPriority 60
    -3.5% operating_income; 2 forward row(s); quote_verified
    The Company currently expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges.
  8. Manufacturing and Capacity · Supply chain & operationsPriority 58
    3 sources (news, press_release, sec_filing); quote_verified
    The new North Carolina facility is expected to become operational in 2-3 years.
  9. Geographic Market Commentary · Geographic mixPriority 57
    +6.4% revenue (realized); quote_verified
    United States revenues for the three months ended June 30, 2026: $1,090.6 million, compared to $1,025.6 million for the three months ended June 30, 2025 (6.3% increase).
  10. Operating Expense Trends · Operating expenses (SG&A)Priority 56
    2 sources (press_release, sec_filing); quote_verified
    Selling, general, and administrative (SG&A) expenses for the three months ended June 30, 2026: $369.7 million, compared to $353.8 million for the three months ended June 30, 2025 (4.5% increase).
  11. Market Demand Trends · Demand, orders & backlogPriority 53
    2 sources (news, press_release); quote_verified
    Investing.com noted analysts are watching Applied Sterilization Technologies (AST) for signs of stabilizing after destocking and anticipated STERIS earnings of $2.50 and revenue of $1.5 billion.
  12. Capital Expenditures and Free Cash Flow · UnclassifiedPriority 49
    quote_verified
    The company increased capital expenditures projections and slightly lowered free cash flow expectations to reflect the new North Carolina investment.

Threads by pillar

Revenue & Demand Priority 88 · 4 threads

Costs & Margins Priority 88 · 7 threads

Capital & Balance Sheet Priority 80 · 5 threads

Strategy & Portfolio Priority 36 · 1 thread

Legal, Regulatory & Policy Priority 34 · 1 thread

Guidance & Outlook Priority 77 · 1 thread

Macro & Market Conditions Priority 25 · 1 thread

Unclassified Priority 71 · 3 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-7.1%+7.1%+2.5%
revenue+6.4%+6.4%+24.4%
cash-0.4%+0.4%-2.0%
assets-0.1%+0.1%+0.1%
margin——+2.8%
net_income——+3.0%